eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases

Copyright West LLC. Minimum 15 minutes delayed.

Recent News Releases
02/13/19
Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
02/06/19
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
01/30/19
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
Upcoming Events
There are currently no events scheduled.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

295 Madison Ave., Suite 2400, New York, NY 10017     +1 (917) 289-1117

[email protected]enoviabio.com